Lamivudine/tenofovir

Lamivudine/tenofovir
Combination of
LamivudineNucleoside reverse transcriptase inhibitor
Tenofovir disoproxilNucleotide reverse transcriptase inhibitor
Names
Trade namesCimduo, Temixys
Clinical data
Routes of
use		By mouth
External links
AHFS/Drugs.comMonograph
MedlinePlusa618039
Legal
License data
Legal status

Lamivudine/tenofovir disoproxil, sold under the brand name Cimduo among others, is a combination medication to treat HIV/AIDS in people weighing more than 35 kilograms (77 lb).[1][3] It is taken by mouth.[1]

It contains lamivudine and tenofovir disoproxil.[1]

Lamivudine/tenofovir was approved for medical use in the United States in February 2018.[1][4]

References

  1. 1 2 3 4 5 "Cimduo- lamivudine and tenofovir disoproxil fumarate tablet, film coated". DailyMed. 22 March 2018. Archived from the original on 15 February 2020. Retrieved 26 March 2020.
  2. ↑ "Temixys- lamivudine and tenofovir disoproxil fumarate tablet, film coated". DailyMed. Archived from the original on 14 February 2022. Retrieved 13 February 2022.
  3. ↑ Waters L, Mehta V, Gogtay J, Boffito M (March 2021). "The evidence for using tenofovir disoproxil fumarate plus lamivudine as a nucleoside analogue backbone for the treatment of HIV". Journal of Virus Eradication. 7 (1): 100028. doi:10.1016/j.jve.2021.100028. PMC 7868802. PMID 33598310.
  4. ↑ "Drug Approval Package: Cimduo (lamivudine and tenofovir disoproxil fumarate)". U.S. Food and Drug Administration (FDA). 27 November 2018. Archived from the original on 26 March 2020. Retrieved 26 March 2020.

Further reading

Identifiers:


This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.